comprehensive -WSS

comprehensive

author：hotspot 2025-09-29 21:21:05 - browse：9

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： 6 phony surgeries that take placebo to the extreme

leisure time

WSS

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Study: Why relieving medical debt did not improve financial outcomes

STAT readers on older presidents, polypills, Medicare, and more

Moderna says combo Covid

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Medical device trials still don't enroll enough women, study finds

Wikipedia

comprehensive

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Ed Silverman on new gene therapies, biosimilars, coffee, and more

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readers discuss the intersection of pregnancy and addiction

Duchenne breakthrough therapy leaves behind pioneering families

Report captures long Covid’s disabling effects and policy challenges

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Wikipedia

Cigna wins case to block Amy Bricker's move to CVS

Statins may not be needed by millions of people, study suggests

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

The Harvard botanist who searched for psychedelics in the Amazon

Obesity drugs seen as possible treatment for liver disease MASH

A new nitrogen execution bill also undermines medical licensing

leisure time

explore

Wikipedia

explore